Company intelligence
PERSICA PHARMACEUTICALS LIMITED
Developing a transformative, non-opioid treatment for patients suffering from chronic Low Back Pain with Modic changes
About PERSICA PHARMACEUTICALS LIMITED
Persica Pharmaceuticals is a clinical-stage company developing PP353, a groundbreaking and transformative treatment for chronic Low Back Pain (cLBP) with Modic changes. PP353 is a non-opioid, one-off treatment which addresses an underlying cause of cLBP, rather than just the symptoms. Our Phase 1b study, the #Modic trial, showed statistically significant and clinically meaningful reductions in pain and disability. We are now in discussions with regulators about advancing to registrational trials.
Verified activity
Signals from PERSICA PHARMACEUTICALS LIMITED
6 published signals
Research & Knowledge
PERSICA PHARMACEUTICALS LIMITED submitted a manuscript to the European Spine Journal as a preprint.
Reported by PERSICA PHARMACEUTICALS LIMITED
Research & Knowledge
PERSICA PHARMACEUTICALS LIMITED published a new analysis showing a clear exposure-response relationship for antibiotic treatment in vertebrogenic lumbar back pain, with higher estimated antibiotic exposure at the disc associated with greater improvement in pain and disability at 12 months.
Reported by PERSICA PHARMACEUTICALS LIMITED
Research & Knowledge
PERSICA PHARMACEUTICALS LIMITED published a Phase 1b trial showing that PP353 produced statistically significant and durable improvements in pain and disability over 12 months, along with reduced analgesic use, including opioids.
Reported by PERSICA PHARMACEUTICALS LIMITED
Products & Services
PERSICA PHARMACEUTICALS LIMITED launched PP353, a targeted, non-opioid treatment for vLBP delivered intradiscally to achieve sustained local exposure.
Reported by PERSICA PHARMACEUTICALS LIMITED
Research & Knowledge
PERSICA PHARMACEUTICALS LIMITED published new analyses highlighting the strong exposure-response relationship between estimated intradiscal antibiotic exposure and clinical outcomes for vertebrogenic Lumbar Back Pain (vLBP).
Reported by Dave Watson
Research & Knowledge
PERSICA PHARMACEUTICALS LIMITED published a research publication examining the relationship between bacterial infection and vertebrigenic lumbar back pain, demonstrating a remarkable relationship between antibiotic exposure and the response.
Reported by Edward Littler